Dr. Lewis disclosed that he consults for AbbVie, Janssen, Prometheus, and Millennium and has received research funding from Centocor and Takeda.
News
Trial immunosuppressive therapy benefits outweigh long-term lymphoma risks in IBD
More IBD & Intestinal Disorders News
- Does Bezlotoxumab Boost FMT Efficacy in IBD Patients With Recurrent CDI?
- Angiotensin Receptor Blockers May Lead to Worse Outcomes in Celiac Disease
- Common Crohn’s Immune Response to Gut Bacteria Suggests Therapeutic Target
- Guselkumab Efficacy in Crohn’s Disease Unaffected by Prior Biologic Use
- IBS: Understanding a Common Yet Misunderstood Condition
- Breath Gas Patterns Predict Response to Low FODMAP Diet
- Ultraprocessed Foods Associated With Relapse Risk in Crohn’s Disease
- Live Rotavirus Vaccine Safe for Newborns of Biologic-Treated Moms With IBD
Question 1 of 5